Department of Cardiology, Kailuan General Hospital, North China University of Science and Technology.
Healthcare Center, Kailuan Medical group, Tangshan.
J Hypertens. 2021 Jun 1;39(6):1221-1229. doi: 10.1097/HJH.0000000000002758.
Using the brachial--ankle pulse wave velocity (baPWV) as a biomarker for arteriosclerosis, we studied the effect of blood pressure (BP) and BP control on arteriosclerosis progression.
The community-based longitudinal Kailuan study included 6552 participants [4938 (75.37%) men] with a mean follow-up of 4.62 ± 2.21 years. Hypertension was defined based on the Joint National Committee (JNC7) criteria and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines. All study participants had hypertension and were stratified as follows according to BP at baseline and follow-up: the normal--normal [normal BP (under therapy) at baseline and final follow-up], normal--hypertensive, hypertensive--normal, and hypertensive--hypertensive groups. Using the JNC7-based hypertension definition, the annual baPWV increase was the highest (P < 0.001) in the hypertensive--hypertensive group [17.32 cm/s; 95% confidence interval [CI]:9.7--24.9], followed by the normal--hypertensive group (14.44 cm/s; 95% CI:5.5--23.4), and the hypertensive--normal group (0.88 cm/s; 95% CI: -7.84 to 9.60), with the normal--normal group as the reference group in a multivariable model. The model additionally included parameters, such as age, baseline baPWV, heart rate, BMI, serum glucose concentration, prevalence of antihypertensive treatment and alcohol consumption, heart rate, and estimated glomerular filtration rate. Applying the ACC/AHA guidelines and the same multivariable model, the annual baPWV increase was the highest (P < 0.001) in the hypertensive--hypertensive group (43.54 cm/s; 95% CI: 22.54--64.55), followed by the normal--hypertensive group (34.01 cm/s; 95% CI: 10.39--57.62) and the hypertensive--normal group (24.12 cm/s; 95% CI: 1.24--47.00).
Lower BP and medical reduction in increased BP were associated with a reduction in the baPWV increase and may delay the progression of arteriosclerosis in hypertensive patients.
以臂踝脉搏波速度(baPWV)作为动脉硬化的生物标志物,我们研究了血压(BP)和血压控制对动脉硬化进展的影响。
基于社区的 Kailuan 研究包括 6552 名参与者[4938 名(75.37%)男性],平均随访 4.62±2.21 年。高血压根据联合国家委员会(JNC7)标准和 2017 年美国心脏病学会/美国心脏协会(ACC/AHA)指南定义。所有研究参与者均患有高血压,并根据基线和随访时的血压分为以下几类:正常-正常[基线和最终随访时的正常血压(治疗中)]、正常-高血压、高血压-正常和高血压-高血压组。使用基于 JNC7 的高血压定义,高血压-高血压组的 baPWV 年增长率最高(P<0.001)[17.32cm/s;95%置信区间(CI):9.7-24.9],其次是正常-高血压组(14.44cm/s;95%CI:5.5-23.4)和高血压-正常组(0.88cm/s;95%CI:-7.84 至 9.60),以多变量模型中的正常-正常组为参考组。该模型还包括年龄、基线 baPWV、心率、BMI、血清葡萄糖浓度、降压治疗和饮酒的患病率、心率和估计肾小球滤过率等参数。应用 ACC/AHA 指南和相同的多变量模型,高血压-高血压组的 baPWV 年增长率最高(P<0.001)[43.54cm/s;95%CI:22.54-64.55],其次是正常-高血压组(34.01cm/s;95%CI:10.39-57.62)和高血压-正常组(24.12cm/s;95%CI:1.24-47.00)。
较低的血压和血压升高的药物降低与 baPWV 升高的降低相关,并可能延迟高血压患者的动脉硬化进展。